Found 7 matching trials
Retlirafusp Alfa Plus Chemotherapy as Neoadjuvant Therapy for Thoracic ESCC PHASE2 This is a prospective, single-arm, exploratory clinical study designed to e...
Show More Location
Tangdu Hospital Affiliated to the Fourth Military Medical University
Learn More & Join Trial
Low-Dose Radiotherapy With Retlirafusp Alfa and Chemotherapy as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma PHASE2 This study aims to evaluate the efficacy and safety of neoadjuvant low-dose...
Show More Status
Active Not Recruiting
Location
Harbin Medical University Cancer Hospital, No. 150 Haping Road, Nangang District, Harbin, Heilongjiang Province, China
Learn More & Join Trial
Relatrilfa-α Plus Single-Agent Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III NSCLC (Phase 2) PHASE2 This is a single-center, single-arm, phase 2 trial evaluating the efficacy ...
Show More Location
Multiple Locations
Learn More & Join Trial
An Umbrella-designed Prospective Multicenter Randomized Open-label Superiority Trial Evaluating Multi-biomarker-guided Precision Therapy for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma PHASE2 This is a prospective, multicenter, randomized, open-label, umbrella superi...
Show More Learn More & Join Trial
An Exploratory Clinical Study of Accurate Efficacy Assessment of Neoadjuvant Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma Based on 68Ga-FAPI ([68Ga] Fibroblast Activation Protein Inhibitor)/¹⁸F-FDG (2-Deoxy-2-[¹⁸F]Fluoro-D-glucose) Dual Imaging PHASE2 This study will evaluate whether two positron emission tomography/computed ...
Show More Location
Zhongshan Hospital, Fudan University
Learn More & Join Trial
Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer PHASE2 To investigate the efficacy and safety of Retlirafusp alfa in combination w...
Show More Location
Harbin Medical University Cancer Hospital
Learn More & Join Trial
Retlirafusp Alfa Combined With Apatinib and Nab-Paclitaxel as Second-line Treatment for Gastric or Gastroesophageal Junction Cancer PHASE2 This is a prospective, single-arm, investigator-initiated phase II clinical...
Show More Location
Henan Cancer Hospital
Learn More & Join Trial